We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors.
The abstract ‘Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors.’ (Abstract number CT180) was presented at AACR 2022, 8-13 April, 2022.
Questions
- What are the current unmet needs in the treatment of ovarian cancer in patients who are naive to PD-1/PD-L1 inhibitors? (0:30)
- What is the potential role of the anti-TIGIT antibody vibostolimab in ovarian cancer management? (1:19)
- How might the efficacy of vibostolimab differ if used in combination with pembrolizumab compared with as a coformulation with pembrolizumab? (2:28)
- What are the current findings of this ongoing phase 1 study of the vibostolimab/ pembrolizumab coformulation? (3:08)
Disclosures: Ruth Perets discloses consulting for MSD.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AACR annual meeting 2022.
